VicPlas International Ltd. (SG:569)
SGX:569
Want to see SG:569 full AI Analyst Report?
569 Stock Chart & Stats
S$0.09
<S$0.01(2.13%)
At close: 4:00 PM EST
S$0.09
<S$0.01(2.13%)
Day’s Range― - ―
52-Week RangeS$0.08 - S$0.10
Previous CloseN/A
Volume100.00
Average Volume (3M)97.25K
Market Cap
S$40.89M
Enterprise ValueS$78.80M
Total Cash (Recent Filing)S$4.71M
Total Debt (Recent Filing)S$41.11M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding511,537,700
10 Day Avg. Volume66,350
30 Day Avg. Volume97,253
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.65
Price to Sales (P/S)0.39
P/FCF Ratio-7.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsVicPlas sells into both piping systems (construction, plumbing, infrastructure) and medical devices (catheters/components). This sector diversification reduces single-market exposure, smoothing revenue cycles and providing durable demand buffers across infrastructure and healthcare over months.
Top-line RecoveryThe company posted a pronounced revenue rebound in 2025 and multi-year revenue growth, indicating recovering end-market demand and commercial traction. Sustained top-line recovery can restore operating leverage and provide a foundation for margin and cash-flow improvement if cost discipline continues.
Healthy Gross MarginsGross margins near the low-50s percent signal product-level profitability and potential pricing or manufacturing efficiency advantages. Such strong gross margins create room to absorb elevated operating costs or invest in R&D/market expansion while retaining a structural cushion for future profit recovery.
Bears Say
Recent Net LossesThe shift to net losses in 2024–2025 erodes retained earnings and constrains reinvestment capacity. Persistent loss-making undermines ROE and may necessitate cost cuts or external funding, limiting strategic flexibility and making recovery dependent on sustained revenue and operating-cost improvements.
Weak Cash GenerationOperating cash flow collapsed and free cash flow turned negative, signaling poor conversion of earnings into cash and tighter funding flexibility. Over the medium term this raises risk to working-capital management, debt service ability, and the capacity to fund capex or strategic initiatives without external financing.
Rising Leverage And Negative ROELeverage increased materially while ROE swung negative, raising financial risk. Higher debt amplifies sensitivity to cash-flow shortfalls and limits flexibility for M&A or capex. Negative equity returns indicate capital is not being deployed profitably, pressuring long-term shareholder value creation.
VicPlas International Ltd. News
569 FAQ
What was VicPlas International Ltd.’s price range in the past 12 months?
VicPlas International Ltd. lowest share price was S$0.07 and its highest was S$0.10 in the past 12 months.
What is VicPlas International Ltd.’s market cap?
VicPlas International Ltd.’s market cap is S$40.89M.
When is VicPlas International Ltd.’s upcoming earnings report date?
VicPlas International Ltd.’s upcoming earnings report date is Sep 25, 2026 which is in 104 days.
How were VicPlas International Ltd.’s earnings last quarter?
VicPlas International Ltd. released its earnings results on Mar 13, 2026. The company reported -S$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.007.
Is VicPlas International Ltd. overvalued?
According to Wall Street analysts VicPlas International Ltd.’s price is currently Overvalued.
Does VicPlas International Ltd. pay dividends?
VicPlas International Ltd. pays a N/A dividend of S$0.004 which represents an annual dividend yield of N/A. See more information on VicPlas International Ltd. dividends here
What is VicPlas International Ltd.’s EPS estimate?
VicPlas International Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VicPlas International Ltd. have?
VicPlas International Ltd. has 511,537,700 shares outstanding.
What happened to VicPlas International Ltd.’s price movement after its last earnings report?
VicPlas International Ltd. reported an EPS of -S$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.124%.
Which hedge fund is a major shareholder of VicPlas International Ltd.?
Currently, no hedge funds are holding shares in SG:569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VicPlas International Ltd.
Vicplas International Ltd, established in Singapore in 1993, operates as an investment holding company with key business segments in medical devices and piping systems. The company's geographical reach includes Singapore, Malaysia, the People's Republic of China, and the United Kingdom. Its piping division focuses on the manufacturing, trading, and distribution of a variety of piping solutions. These systems are utilized for diverse applications such as waste and potable water management in residential, educational, commercial, and industrial settings; conduits for underground electrical and internal building wiring; and data and signal lines for telecommunication providers. Additionally, Vicplas is engaged in the design, development, production, and assembly of both sterile and non-sterile medical devices. The company also offers specialized project design and engineering services. Vicplas International Ltd is a subsidiary of Venner Capital S.A.
Technical Analysis
Asiamedic Limited
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Alliance Healthcare Group Ltd.
―
Medinex Ltd.
―